Innovimmune Biotherapeutics is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary small molecule NME immunomodulatory drugs for the treatment of Autoimmune & Immuno-Inflammatory Diseases and Cancer.



Our Goal

To discover and develop First-in-Class NME inmunotherapies. We are building an innovative product pipeline of novel small molecule NME immunomodulatory drug candidates targeting cytokine, chemokine, nuclear hormone receptor and signal transduction pathways critical in the pathogenesis of the specialty therapeutic areas of Autoimmunity, Immuno-Inflammation and Immuno-Oncology.